Novo Nordisk today announced plans to invest more than 17 bn Danish kroner in construction of three new manufacturing facilities as well as expansion of one existing facility at its production site in Kalundborg, Denmark.
The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity. These expansions will provide capacity for the production of Novo Nordisk’s current and future oral and injectable products. The new facilities will be automated and include state-of-the-art production technologies.
“This major investment in our manufacturing facilities in Kalundborg is an important step in building and ensuring future capacity for production of our current and future oral and injectable product portfolio. Kalundborg is currently the cornerstone in our production of API and the expansion of the manufacturing capacity is important to meeting the future demands of patients. The investment announced today emphasises our continued commitment to Denmark and Kalundborg being at the heart of our global manufacturing setup”, said Henrik Wulff, EVP, Product Supply, Quality & IT, Novo Nordisk.
The investment projects are expected to be finalised in 2027 and will create around 400 new jobs. More than 2,500 external staff will be engaged in the building phase.
Facts about Novo Nordisk manufacturing in Kalundborg
Novo Nordisk’s production facilities in Kalundborg were established in 1969. Today, the facilities cover an area of 1,200,000 m2 and employ about 3,200 people. In Kalundborg, Novo Nordisk manufactures products for the treatment of obesity and diabetes as well as several biopharmaceutical products. Since the turn of the millennium and until today, Novo Nordisk has invested more than 18 bn Danish kroner in the production facilities in Kalundborg. The investment announced today almost doubles 20 years of investments.
By Novo Nordisk, Press Release
Source: novonordisk.com
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
